Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Efficacy of Dapagliflozin on Renal Function and Outcomes in Patients With Heart Failure With Reduced Ejection Fraction
Pardeep S. Jhund, Scott D. Solomon, Kieran F. Docherty, et al.
Circulation (2020) Vol. 143, Iss. 4, pp. 298-309
Open Access | Times Cited: 244

Showing 1-25 of 244 citing articles:

2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure
Theresa A. McDonagh, Marco Metra, Marianna Adamo, et al.
European Heart Journal (2021) Vol. 42, Iss. 36, pp. 3599-3726
Open Access | Times Cited: 8803
2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure
Theresa McDonagh, Marco Metra, Marianna Adamo, et al.
European Journal of Heart Failure (2022) Vol. 24, Iss. 1, pp. 4-131
Open Access | Times Cited: 1537
KDIGO 2022 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease
Peter Rossing, Maria Luiza Caramori, Juliana C.N. Chan, et al.
Kidney International (2022) Vol. 102, Iss. 5, pp. S1-S127
Open Access | Times Cited: 724
Effects of dapagliflozin on major adverse kidney and cardiovascular events in patients with diabetic and non-diabetic chronic kidney disease: a prespecified analysis from the DAPA-CKD trial
David C. Wheeler, Bergur V. Stefánsson, Niels Jongs, et al.
The Lancet Diabetes & Endocrinology (2020) Vol. 9, Iss. 1, pp. 22-31
Open Access | Times Cited: 409
American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan—2022 Update
Lawrence Blonde, Guillermo E. Umpierrez, Sarah Reddy, et al.
Endocrine Practice (2022) Vol. 28, Iss. 10, pp. 923-1049
Open Access | Times Cited: 321
Cellular and molecular pathobiology of heart failure with preserved ejection fraction
Sumita Mishra, David A. Kass
Nature Reviews Cardiology (2021) Vol. 18, Iss. 6, pp. 400-423
Open Access | Times Cited: 292
2023 ACC Expert Consensus Decision Pathway on Comprehensive Multidisciplinary Care for the Patient With Cardiac Amyloidosis
M. Kittleson, Frederick L. Ruberg, Amrut V. Ambardekar, et al.
Journal of the American College of Cardiology (2023) Vol. 81, Iss. 11, pp. 1076-1126
Open Access | Times Cited: 287
CCS/CHFS Heart Failure Guidelines Update: Defining a New Pharmacologic Standard of Care for Heart Failure With Reduced Ejection Fraction
Michael McDonald, Sean Virani, Michael Chan, et al.
Canadian Journal of Cardiology (2021) Vol. 37, Iss. 4, pp. 531-546
Open Access | Times Cited: 242
Patient profiling in heart failure for tailoring medical therapy. A consensus document of the Heart Failure Association of the European Society of Cardiology
Giuseppe Rosano, Brenda Moura, Marco Metra, et al.
European Journal of Heart Failure (2021) Vol. 23, Iss. 6, pp. 872-881
Open Access | Times Cited: 231
Effects of Early Empagliflozin Initiation on Diuresis and Kidney Function in Patients With Acute Decompensated Heart Failure (EMPAG-HF)
P. Christian Schulze, Jürgen Bogoviku, Julian Westphal, et al.
Circulation (2022) Vol. 146, Iss. 4, pp. 289-298
Open Access | Times Cited: 150
Kidney Function and Outcomes in Patients Hospitalized With Heart Failure
Ravi B. Patel, Gregg C. Fonarow, Stephen J. Greene, et al.
Journal of the American College of Cardiology (2021) Vol. 78, Iss. 4, pp. 330-343
Open Access | Times Cited: 141
Renal Protection with SGLT2 Inhibitors: Effects in Acute and Chronic Kidney Disease
Clifford J. Bailey, Caroline Day, Srikanth Bellary
Current Diabetes Reports (2022) Vol. 22, Iss. 1, pp. 39-52
Open Access | Times Cited: 140
Effect of dapagliflozin on the rate of decline in kidney function in patients with chronic kidney disease with and without type 2 diabetes: a prespecified analysis from the DAPA-CKD trial
Hiddo J.L. Heerspink, Niels Jongs, Glenn M. Chertow, et al.
The Lancet Diabetes & Endocrinology (2021) Vol. 9, Iss. 11, pp. 743-754
Open Access | Times Cited: 136
Rapid evidence‐based sequencing of foundational drugs for heart failure and a reduced ejection fraction
Milton Packer, John J.V. McMurray
European Journal of Heart Failure (2021) Vol. 23, Iss. 6, pp. 882-894
Open Access | Times Cited: 130
Evidence-Based Medical Therapy in Patients With Heart Failure With Reduced Ejection Fraction and Chronic Kidney Disease
Iris E. Beldhuis, Carolyn S.P. Lam, Jeffrey M. Testani, et al.
Circulation (2022) Vol. 145, Iss. 9, pp. 693-712
Open Access | Times Cited: 123
Kidney and heart failure outcomes associated with SGLT2 inhibitor use
Annemarie B. van der Aart‐van der Beek, Rudolf A. de Boer, Hiddo J.L. Heerspink
Nature Reviews Nephrology (2022) Vol. 18, Iss. 5, pp. 294-306
Open Access | Times Cited: 115
A kidney perspective on the mechanism of action of sodium glucose co-transporter 2 inhibitors
Taha Sen, Hiddo J.L. Heerspink
Cell Metabolism (2021) Vol. 33, Iss. 4, pp. 732-739
Open Access | Times Cited: 111
Sodium–glucose co‐transporter 2 inhibitors as an early, first‐line therapy in patients with heart failure and reduced ejection fraction
Daniela Tomasoni, Gregg C. Fonarow, Marianna Adamo, et al.
European Journal of Heart Failure (2021) Vol. 24, Iss. 3, pp. 431-441
Open Access | Times Cited: 108
Initial Decline (Dip) in Estimated Glomerular Filtration Rate After Initiation of Dapagliflozin in Patients With Heart Failure and Reduced Ejection Fraction: Insights From DAPA-HF
Carly Adamson, Kieran F. Docherty, Hiddo J.L. Heerspink, et al.
Circulation (2022) Vol. 146, Iss. 6, pp. 438-449
Open Access | Times Cited: 97
Design, recruitment, and baseline characteristics of the EMPA-KIDNEY trial
William G. Herrington, Christoph Wanner, Jennifer B. Green, et al.
Nephrology Dialysis Transplantation (2022) Vol. 37, Iss. 7, pp. 1317-1329
Open Access | Times Cited: 95
Renal effects of guideline‐directed medical therapies in heart failure: a consensus document from the Heart Failure Association of the European Society of Cardiology
Wilfried Müllens, Pieter Martens, Jeffrey M. Testani, et al.
European Journal of Heart Failure (2022) Vol. 24, Iss. 4, pp. 603-619
Open Access | Times Cited: 93
Guía ESC 2021 sobre el diagnóstico y tratamiento de la insuficiencia cardiaca aguda y crónica
Theresa A. McDonagh, Marco Metra, Marianna Adamo, et al.
Revista Española de Cardiología (2022) Vol. 75, Iss. 6, pp. 523.e1-523.e114
Closed Access | Times Cited: 89
Accelerated and personalized therapy for heart failure with reduced ejection fraction
Li Shen, Pardeep Singh Jhund, Kieran F. Docherty, et al.
European Heart Journal (2022) Vol. 43, Iss. 27, pp. 2573-2587
Open Access | Times Cited: 82
Dapagliflozin and Kidney Outcomes in Patients With Heart Failure With Mildly Reduced or Preserved Ejection Fraction
Finnian R. Mc Causland, Brian Claggett, Muthiah Vaduganathan, et al.
JAMA Cardiology (2022) Vol. 8, Iss. 1, pp. 56-56
Open Access | Times Cited: 77
2024 ACC Expert Consensus Decision Pathway for Treatment of Heart Failure With Reduced Ejection Fraction
Thomas M. Maddox, James L. Januzzi, Larry A. Allen, et al.
Journal of the American College of Cardiology (2024) Vol. 83, Iss. 15, pp. 1444-1488
Closed Access | Times Cited: 71
Page 1 - Next Page

Scroll to top